Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Gotham Asset Management LLC

Gotham Asset Management LLC raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 386.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,827 shares of the medical equipment provider’s stock after acquiring an additional 40,384 shares during the quarter. Gotham Asset Management LLC’s holdings in Zimmer Biomet were worth $5,369,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Focus Partners Wealth grew its position in Zimmer Biomet by 16.2% in the 4th quarter. Focus Partners Wealth now owns 16,528 shares of the medical equipment provider’s stock valued at $1,760,000 after acquiring an additional 2,303 shares in the last quarter. Ensign Peak Advisors Inc boosted its stake in shares of Zimmer Biomet by 7.3% in the 4th quarter. Ensign Peak Advisors Inc now owns 58,523 shares of the medical equipment provider’s stock valued at $6,182,000 after buying an additional 4,000 shares during the period. Deutsche Bank AG boosted its stake in shares of Zimmer Biomet by 0.3% in the 4th quarter. Deutsche Bank AG now owns 922,403 shares of the medical equipment provider’s stock valued at $97,433,000 after buying an additional 3,170 shares during the period. Dean Capital Management boosted its stake in shares of Zimmer Biomet by 18.0% in the 4th quarter. Dean Capital Management now owns 16,217 shares of the medical equipment provider’s stock valued at $1,713,000 after buying an additional 2,473 shares during the period. Finally, Dunhill Financial LLC boosted its stake in shares of Zimmer Biomet by 86.6% in the 4th quarter. Dunhill Financial LLC now owns 444 shares of the medical equipment provider’s stock valued at $47,000 after buying an additional 206 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Trading Down 0.9%

ZBH opened at $97.32 on Wednesday. The firm has a market cap of $19.25 billion, a price-to-earnings ratio of 21.87, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The business’s 50 day moving average is $104.14 and its two-hundred day moving average is $106.04. Zimmer Biomet Holdings, Inc. has a 52 week low of $89.92 and a 52 week high of $122.17.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. The business had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The company’s revenue for the quarter was up 1.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.94 earnings per share. On average, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.99%. The ex-dividend date was Monday, March 31st. Zimmer Biomet’s payout ratio is currently 21.24%.

Insider Activity

In related news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. The trade was a 14.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.39% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ZBH shares. Morgan Stanley decreased their price objective on Zimmer Biomet from $115.00 to $95.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 6th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Robert W. Baird decreased their price objective on Zimmer Biomet from $130.00 to $115.00 and set an “outperform” rating for the company in a research note on Tuesday, May 6th. BTIG Research reissued a “buy” rating on shares of Zimmer Biomet in a research report on Monday, April 14th. Finally, The Goldman Sachs Group cut their target price on Zimmer Biomet from $120.00 to $104.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $113.45.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.